scholarly journals Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo

2011 ◽  
Vol 130 (3) ◽  
pp. 694-704 ◽  
Author(s):  
Maria Graziella Catalano ◽  
Mariateresa Pugliese ◽  
Eleonora Gargantini ◽  
Cristina Grange ◽  
Benedetta Bussolati ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cytotoxic Activity ◽  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Anaplastic Thyroid Cancer ◽  
Deacetylase Inhibitor

Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo

2002 ◽  
Vol 64 (7) ◽  
pp. 1079-1090 ◽  
Author(s):  
Yuka Sasakawa ◽  
Yoshinori Naoe ◽  
Takeshi Inoue ◽  
Tatsuya Sasakawa ◽  
Masahiko Matsuo ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Deacetylase Inhibitor ◽  
Human Lymphoma

scholarly journals Histone deacetylase inhibitor MPT0B291 suppresses Glioma Growth in vitro and in vivo partially through acetylation of p53

2020 ◽  
Vol 16 (16) ◽  
pp. 3184-3199
Author(s):  
Batsaikhan Buyandelger ◽  
Eli E Bar ◽  
Kuo-Sheng Hung ◽  
Ruei-Ming Chen ◽  
Yung-Hsiao Chiang ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Deacetylase Inhibitor ◽  
Glioma Growth

scholarly journals The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth

2014 ◽  
Vol 190 (1) ◽  
pp. 191-197 ◽  
Author(s):  
Eric Weinlander ◽  
Yash Somnay ◽  
April D. Harrison ◽  
Cheng Wang ◽  
Yi-Qiang Cheng ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Anaplastic Thyroid Cancer ◽  
Cancer Growth ◽  
The Novel ◽  
Deacetylase Inhibitor

scholarly journals Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Maria Graziella Catalano ◽  
Mariateresa Pugliese ◽  
Marco Gallo ◽  
Enrico Brignardello ◽  
Paola Milla ◽  
...  
Keyword(s):  
Valproic Acid ◽  
Overall Survival ◽  
Thyroid Cancer ◽  
Disease Progression ◽  
Histone Deacetylase ◽  
Median Survival ◽  
Histone Deacetylase Inhibitor ◽  
Anaplastic Thyroid Cancer ◽  
Randomized Controlled ◽  
Deacetylase Inhibitor

Anaplastic thyroid cancer (ATC) has a median survival less than 5 months and, to date, no effective therapy exists. Taxanes have recently been stated as the main drug treatment for ATC, and the histone deacetylase inhibitor valproic acid efficiently potentiates the effects of paclitaxelin vitro. Based on these data, this trial assessed the efficacy and safety of the combination of paclitaxel and valproic acid for the treatment of ATC. This was a randomized, controlled phase II/III trial, performed on 25 ATC patients across 5 centers in northwest Italy. The experimental arm received the combination of paclitaxel (80 mg/m2/weekly) and valproic acid (1,000 mg/day); the control arm received paclitaxel alone. Overall survival and disease progression, evaluated in terms of progression-free survival, were the primary outcomes. The secondary outcome was the pharmacokinetics of paclitaxel. The coadministration of valproic acid did not influence the pharmacokinetics of paclitaxel. Neither median survival nor median time to progression was statistically different in the two arms. Median survival of operated-on patients was significantly better than that of patients who were not operated on. The present trial demonstrates that the addition of valproic acid to paclitaxel has no effect on overall survival and disease progression of ATC patients. This trial is registered withEudraCT 2008-005221-11.

scholarly journals Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo

Leukemia ◽  
2004 ◽  
Vol 18 (12) ◽  
pp. 1951-1963 ◽  
Author(s):  
E Weisberg ◽  
L Catley ◽  
J Kujawa ◽  
P Atadja ◽  
S Remiszewski ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Myeloid Leukemia ◽  
Leukemia Cells ◽  
Significant Activity ◽  
Deacetylase Inhibitor
Sign in / Sign up

Export Citation Format

Share Document